Clin2
NCT06868381Possibly a fitNot yet recruiting

Baricitinib for active cardiac sarcoidosis

Cardiac Sarcoidosis

Treatments studied

Part of Blood & lymphatic, Immune system & allergy clinical trials.

This trial tests a medication called baricitinib (a JAK inhibitor) for people with active cardiac sarcoidosis. It may help reduce inflammation in the heart and improve heart function.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
10 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You have been diagnosed with cardiac sarcoidosis (heart sarcoidosis) and have a heart PET scan showing active inflammation within the last 6 weeks.
  • You are not currently taking strong immunosuppressants like biologics or other JAK inhibitors, or you are on low-dose prednisone (≤20 mg daily) or a steroid-sparing drug like methotrexate.
  • You have not had a blood clot (DVT or pulmonary embolism) and are not at high risk for one.
  • You do not currently smoke cigarettes.
  • Your kidney function is good (estimated GFR ≥30) and your blood counts and liver tests are within safe limits.
  • You do not have an active infection or recent cancer (except certain treated skin or cervical cancers).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03593759Recruiting· Phase 3
Testing treatment for active cardiac sarcoidosis heart rhythm and function

This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.

New Haven, Connecticut
NCT06660732Recruiting· Phase 2
Study of Rilonacept for cardiac sarcoidosis

This trial tests if rilonacept can help people with cardiac sarcoidosis, a condition where inflammation affects the heart. You may join if you have active inflammation on a PET scan despite standard treatments.

Baltimore, Maryland
NCT07159074Recruiting· Phase 2
Testing tilmanocept for heart inflammation in sarcoidosis

This study tests whether a tracing agent called tilmanocept can help doctors see inflammation in the heart caused by sarcoidosis. It may provide a new way to diagnose and monitor cardiac sarcoidosis without invasive procedures.

Durham, North Carolina
NCT05954507Recruiting
PET/MRI scan to assess heart risk in sarcoidosis

This study checks whether a special heart scan called PET/MRI can predict how sarcoidosis may affect your heart. It may help doctors better estimate heart risk and plan follow-up based on scan findings.

Créteil
NCT06131112Recruiting
PET scan for heart inflammation in sarcoidosis

This study tests if a special PET scan with 64Cu-DOTATATE can detect inflammation in the heart caused by sarcoidosis. It may help diagnose heart sarcoidosis more accurately in people with symptoms or known disease.

Copenhagen
NCT01477359Recruiting
Sarcoidosis and the heart: a long-term study

This study follows people with sarcoidosis that may or may not be affecting the heart. It uses special scans (PET and MRI) to look for heart involvement and track how the disease changes over time.

Calgary, Alberta

Hear when a new Cardiac Sarcoidosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.